


Report No.77

JANUARY - MARCH 1979

CENTER FOR DISEASE CONTROL  
**BIOLOGICS**  
**SURVEILLANCE**

RECEIVED  
AUG 2 1979

EDC LIBRARY  
ATLANTA, GA. 30333



COOPERATING IN THIS PROGRAM ARE THE FOLLOWING:

Armour Pharmaceutical Company

Connaught Laboratories

Hyland Laboratories

Lederle Laboratories

Eli Lilly and Company

Massachusetts Department of Public Health

Merck Sharp & Dohme

Michigan Department of Health

Parke, Davis & Company

Sclavo, Inc.

Texas State Department of Health

Wyeth Laboratories

CENTER FOR DISEASE CONTROL

IMMUNIZATION PRACTICES  
ADVISORY COMMITTEE

BUREAU OF STATE SERVICES

IMMUNIZATION DIVISION

BIOLOGICS SURVEILLANCE

William H. Foege, M.D.  
Director

Alan R. Hinman, M.D.  
Acting Executive Secretary

J. D. Millar, M.D.  
Director

Alan R. Hinman, M.D.  
Director

Donald L. Eddins, Chief  
Dona D. Ludwig

FOR ADMINISTRATIVE USE ONLY

## BIOLOGICS SURVEILLANCE

This summary is intended primarily for those concerned with the national use and application of immunizing agents. Although the "Net Distribution" figures are recognized as representing rough approximations only, we believe that a continuing analysis of this kind, interpreted in the light of national and local immunization surveys, will aid in assessing the overall immunization status of the population. It is anticipated that a knowledge of utilization and inventory data will assist in foreseeing possible critical shortages in vaccine supply.

Each major antigen is represented in the form of a line graph showing "Estimated Net Distribution" for the previous year and through the current month of this year. Estimated net distribution represents doses of each vaccine distributed for use during the reporting period and is depicted as gross sales or distribution less recordable returned doses. In addition, specific data is tabulated for each antigen reported during this quarter and is cumulated from the first of the year until present time. Civilian and military data have been combined.

To maintain confidentiality of an individual commercial manufacturer's report for economic and production reasons, current tabulations are available only when at least three producers market and report figures for essentially the same product. This is a basic agreement of the Biologics Surveillance program.

In some instances, where adequate time has elapsed since production and distribution, manufacturers have allowed the data to be released when not all the criteria of confidentiality could be met. Addition of these data to the summaries completes the "natural history" of early patterns of vaccine utilization.

## MONTHLY BIOLOGIC SUMMARY FOR JANUARY 1979

PRODUCT DESCRIPTION	NET NUMBER OF DOSES SOLD OR DISTRIBUTED THIS MONTH	GROSS NUMBER OF DOSES SOLD OR DISTRIBUTED THIS MONTH	NUMBER OF DOSES RETURNED DURING MONTH	NUMBER OF FINISHED DOSES READY FOR IMMEDIATE SHIPMENT AT MONTH END	NUMBER OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIPMENT
Influenza Virus Vaccine, Bivalent***	-237,810	28,850	266,660	404,040	0
, Monovalent	- 19,810	0	19,810	0	0
Diphtheria Toxoid with Tetanus Toxoid (pediatric)	43,057	51,417	8,360	843,840	261,907
Diphtheria and Tetanus Toxoids with Pertussis Vaccine	1,495,783	1,540,863	45,080	1,559,303	1,798,262
Tetanus Toxoid with Diphtheria Toxoid (adult)	565,788	576,615	10,827	2,027,727	51,337
Diphtheria Toxoid	0	0	0	1,730	1,900
Tetanus Toxoid	772,568	809,486	36,918	3,678,108	874,885
Pertussis Vaccine	1,310	1,310	0	5,720	10,760
Poliomyelitis Vaccine, Live, Oral, Trivalent	1,742,780	1,742,780	0	6,675,460	0
Poliomyelitis Vaccine, (Inactivated)	0	0	0	0	0
Measles Virus Vaccine, Live, Attenuated*	693,004	713,740	20,736	544,668	0
Rubella Virus Vaccine, Live*	610,833	660,384	49,551	494,060	0
Mumps Virus Vaccine, Live*	436,601	0	0	0	0
Smallpox Vaccine	109,501	125,301	15,800	1,054,365	22,067,725
Rabies Vaccine	**	**	**	**	**
Immune Serum Globulin, Human (reported in cc's)	428,949	438,801	9,852	607,036	279,122
Tetanus Immune Globulin, Human (reported in cc's)	151,043	153,534	2,491	241,073	41,348

*\*all products containing this antigen*

**\*\*not shown since fewer than three distributors reported**

\*\*\*includes polyvalent and bivalent vaccines

## MONTHLY BIOLOGIC SUMMARY FOR FEBRUARY 1979

PRODUCT DESCRIPTION	NET NUMBER OF DOSES SOLD OR DISTRIBUTED THIS MONTH	GROSS NUMBER OF DOSES SOLD OR DISTRIBUTED THIS MONTH	NUMBER OF DOSES RETURNED DURING MONTH	NUMBER OF FINISHED DOSES READY FOR IMMEDIATE SHIPMENT AT MONTH END	NUMBER OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIPMENT
Influenza Virus Vaccine, Bivalent*** , Monovalent	-311,400 - 11,390	12,710 0	324,110 11,390	432,280 0	0 0
Diphtheria Toxoid with Tetanus Toxoid (pediatric)	32,297	38,987	6,690	909,360	99,427
Diphtheria and Tetanus Toxoids with Pertussis Vaccine	1,195,538	1,236,368	40,830	2,858,268	719,340
Tetanus Toxoid with Diphtheria Toxoid (adult)	610,301	624,248	13,947	1,922,927	311,971
Diphtheria Toxoid	20	20	0	1,710	1,900
Tetanus Toxoid	704,257	722,395	18,138	3,605,488	1,237,324
Pertussis Vaccine	9,130	9,130	0	40,270	10,760
Poliomyelitis Vaccine, Live, Oral, Trivalent	1,613,635	1,613,635	0	6,766,195	0
Poliomyelitis Vaccine, (Inactivated)	6,697	6,697	0	0	0
Measles Virus Vaccine, Live, Attenuated*	535,119	553,770	18,651	200,871	0
Rubella Virus Vaccine, Live*	455,696	455,696	0	465,723	0
Mumps Virus Vaccine, Live*	294,305	294,305	0	0	0
Smallpox Vaccine	696,075	703,825	7,750	333,825	23,230,040
Rabies Vaccine	**	**	**	**	**
Immune Serum Globulin, Human <i>(reported in cc's)</i>	332,059	347,127	15,068	484,088	420,914
Tetanus Immune Globulin, Human <i>(reported in cc's)</i>	80,133	82,681	2,548	201,945	56,942

*\*all products containing this antigen*

*\*\*not shown since fewer than three distributors reported*

\*\*\*includes polyvalent and bivalent vaccines

## MONTHLY BIOLOGIC SUMMARY FOR MARCH 1979

PRODUCT DESCRIPTION	NET NUMBER OF DOSES SOLD OR DISTRIBUTED THIS MONTH	GROSS NUMBER OF DOSES SOLD OR DISTRIBUTED THIS MONTH	NUMBER OF DOSES RETURNED DURING MONTH	NUMBER OF FINISHED DOSES READY FOR IMMEDIATE SHIPMENT AT MONTH END	NUMBER OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIPMENT
Influenza Virus Vaccine, Bivalent***	-319,970	6,550	326,520	415,350	0
, Monovalent	- 14,280	0	14,280	0	0
Diphtheria Toxoid with Tetanus Toxoid (pediatric)	49,766	59,846	10,080	902,440	178,284
Diphtheria and Tetanus Toxoids with Pertussis Vaccine	1,460,709	1,506,419	45,710	2,962,499	60,034
Tetanus Toxoid with Diphtheria Toxoid (adult)	854,780	874,336	19,556	1,987,966	890,245
Diphtheria Toxoid	420	420	0	1,690	1,900
Tetanus Toxoid	863,635	889,189	25,554	3,731,543	1,155,861
Pertussis Vaccine	260	260	0	40,010	10,760
Poliomyelitis Vaccine, Live, Oral, Trivalent	2,005,720	2,005,720	0	8,950,845	0
Poliomyelitis Vaccine, (Inactivated)	13,408	13,408	0	0	0
Measles Virus Vaccine, Live, Attenuated*	690,581	713,002	22,421	358,300	0
Rubella Virus Vaccine, Live*	629,442	631,368	1,926	519,676	0
Mumps Virus Vaccine, Live*	399,763	399,763	0	0	0
Smallpox Vaccine	118,604	125,104	6,500	286,490	23,150,450
Rabies Vaccine	**	**	**	**	**
Immune Serum Globulin, Human (reported in cc's)	268,154	403,722	135,568	191,166	611,648
Tetanus Immune Globulin, Human (reported in cc's)	98,234	101,001	2,767	121,177	41,348

*\*all products containing this antigen*

**\*\*not shown since fewer than three distributors reported**

\*\*\*includes polyvalent and bivalent vaccines

## 1979

\*\*\*includes polyvalent and bivalent vaccines


# ADDENDUM TO BIOLOGIC SURVEILLANCE REPORT

The Net Distribution of Biologics for 1978, Report # 76, should be corrected as follows:	Net Number of Doses Sold or Distributed	
Influenza Virus Vaccine, Bivalent***	17,733,890	


\*\*\*includes polyvalent and bivalent vaccines




**Figure 1**  
**DIPHTHERIA TOXOID, PERTUSSIS VACCINE, AND TETANUS TOXOID**  
**NET DISTRIBUTION BY MONTH – UNITED STATES**



**Figure 2**  
**LIVE ATTENUATED MEASLES VACCINE\***  
**NET DISTRIBUTION BY MONTH – UNITED STATES**



**Figure 3**  
**LIVE RUBELLA VACCINE\***  
**NET DISTRIBUTION BY MONTH – UNITED STATES**



**Figure 4**  
**Mumps Vaccine\***  
**Net Distribution By Month — United States**




Figure 5  
SMALLPOX VACCINE  
NET DISTRIBUTION BY MONTH - UNITED STATES




Figure 6  
BIVALENT INFLUENZA VIRUS VACCINE  
NET DISTRIBUTION BY MONTH – UNITED STATES




Figure 7  
 IMMUNE SERUM GLOBULIN (HUMAN)  
 NET DISTRIBUTION BY MONTH - UNITED STATES




Figure 8  
 TETANUS IMMUNE GLOBULIN  
 NET DISTRIBUTION BY MONTH - UNITED STATES

